An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Trial Status: active
This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study
designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics
(PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with
cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r
higher-risk myelodysplastic syndromes (HR-MDS).
The study consists of 2 parts:
- Part 1: Dose Escalation (DE) in both monotherapy and in combination.
- Part 2: Dose Optimization
Inclusion Criteria
Pathological diagnosis of either: AML according to World Health Organization (WHO) 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts (acute promyelocytic leukemia is excluded but secondary AML and treatment-related AML can be included); Higher-risk (IPSS-R Intermediate, High or Very High Risk at time of study entry) myelodysplastic syndromes (HR-MDS) according to WHO 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Adequate hepatic and renal function measured within 7 days prior to the first dose of eganelisib.
Exclusion Criteria
Autologous or allogeneic stem cell transplant within 6 months prior to Cycle 1 Day
- Receiving immunosuppressants (eg, cyclosporin) or systemic steroids (except for steroid use as cortisol replacement therapy in documented adrenal insufficiency).
Active fungal disease or uncontrolled infection of any kind; patients receiving antibiotic, antifungal or antiviral treatment must be afebrile and hemodynamically stable for >72 hours prior to treatment
WBC count >25 × 10^9/L measured within 7 days prior to the first dose of eganelisib (hydroxyurea is permitted to decrease the WBC count).
Presence of a clinically significant non-hematologic toxicity of prior therapy that has not resolved to Grade ≤1 or Baseline, whichever is worst, as determined by NCI CTCAE v 5.0, except alopecia or skin pigmentation. Fatigue and neuropathy must have resolved to Grade ≤2.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06533761.
